Composition for sterilization

Abstract

To provide a composition that efficiently kill Fusobacterium, which is a bacterium mediating plaque formation, in order to efficiently inhibit plaque formation.SOLUTION: The present invention discloses a bactericidal composition for Fusobacterium that contains an alkyl glucoside having a C8-10 alkyl group and cetylpyridinium chloride, and a plaque formation inhibitory composition that contains an alkyl glucoside having a C8-10 alkyl group and cetylpyridinium chloride. Preferably, the alkyl glucoside is one having a monosaccharide combined with a C8-10 linear alkyl group, and the monosaccharide is glucose.SELECTED DRAWING: None

Description

Technical Field

[0001] The present disclosure relates to a composition for sterilization and the like, and more particularly to a composition for killing Fusobacterium and the like. The contents of all documents described in this specification are incorporated herein by reference.

Background Art

[0002] Plaque is a biofilm formed by the aggregation of oral microorganisms and is considered to be a cause of dental caries and periodontal disease.

[0003] Generally speaking, plaque is formed as follows. That is, first, a thin film of protein derived from saliva and physiological gingival sulcus exudate called "pellicle" is formed on the surface of teeth, and facultative anaerobic bacteria such as Streptococcus attach to the tooth surface through the pellicle. Bacteria such as Fusobacterium that co-aggregate with various oral bacteria adhere to the initial adherent bacteria, and late adherent bacteria such as Porphyromonas gingivalis and Treponema denticola, which are anaerobic bacteria, further adhere and aggregate through the mediator bacteria, and the plaque matures. In particular, late adherent bacteria are known to cause periodontal disease and are directly or indirectly related to the destruction of periodontal tissues. Therefore, suppressing the formation of plaque on the tooth surface, particularly suppressing the adhesion and aggregation of late adherent bacteria and the maturation of plaque, is considered important for preventing periodontal disease.

Prior Art Documents

Non-Patent Documents

[0004]

Non-Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0005] The inventors focused on Fusobacterium, a mediating bacterium, and conducted studies. If the function of Fusobacterium, a mediating bacterium capable of coaggregating with various bacteria, can be suppressed, it is considered possible to suppress the adhesion and aggregation of late colonizing bacteria to the tooth surface, and ultimately suppress the maturation of plaque formation.

[0006] Therefore, the inventors proceeded with the study on the method for sterilizing Fusobacterium.

Means for Solving the Problems

[0007] When proceeding with the study on the method for sterilizing Fusobacterium, it was found that Fusobacterium can be efficiently sterilized by using a combination of a specific alkyl glucoside and cetylpyridinium chloride, and further improvements were made.

[0008] This disclosure includes, for example, the subject matters described in the following items. Item 1. A composition for sterilizing Fusobacterium containing an alkyl glucoside having an alkyl group with 8 to 10 carbon atoms and cetylpyridinium chloride. Item 2. A composition for suppressing plaque formation containing an alkyl glucoside having an alkyl group with 8 to 10 carbon atoms and cetylpyridinium chloride. Item 3. The composition according to Item 1 or 2, wherein the alkyl glucoside having an alkyl group with 8 to 10 carbon atoms is an alkyl glucoside having a structure in which a linear alkyl group with 8 to 10 carbon atoms is bonded to a monosaccharide. Item 4. The composition according to Item 3, wherein the monosaccharide is glucose. Item 5. The composition according to any one of Items 1 to 4, which is an oral composition.

Effects of the Invention

[0009] A method for efficiently sterilizing Fusobacterium, which is a mediating bacterium in plaque formation, is provided. This makes it possible to efficiently suppress plaque formation.

Brief Description of the Drawings

[0010]

Figure 1

Modes for Carrying Out the Invention

[0011] Hereinafter, each embodiment included in the present disclosure will be described in more detail. The present disclosure preferably includes compositions such as a composition for sterilizing Fusobacterium and a composition for suppressing plaque formation, but is not limited thereto, and the present disclosure includes all that are disclosed in this specification and can be recognized by those skilled in the art.

[0012] Compositions such as the composition for sterilizing Fusobacterium and the composition for suppressing plaque formation included in the present disclosure contain an alkyl glucoside having an alkyl group with 8 to 10 carbon atoms (C8 to C10) and cetylpyridinium chloride. The composition according to the present disclosure containing the alkyl glucoside and cetylpyridinium chloride may be referred to as the composition of the present disclosure, and the alkyl glucoside may be referred to as the alkyl glucoside of the present disclosure. Further, cetylpyridinium chloride may be abbreviated as CPC.

[0013] The alkyl glucoside of the present disclosure has a structure in which an alkyl group having 8 to 10 carbon atoms is bonded to a monosaccharide (more specifically, a hydrogen atom of the OH group of the monosaccharide is substituted with an alkyl group having 8 to 10 carbon atoms). Examples of the number of alkyl groups having 8 to 10 carbon atoms bonded to the monosaccharide include 1, 2, or 3, and particularly 1 is preferable. Further, as long as an alkyl group having 8 to 10 carbon atoms is bonded, other alkyl groups may be further bonded, but it is preferable that only an alkyl group having 8 to 10 carbon atoms is bonded.

[0014] The alkyl group having 8 to 10 carbon atoms (8, 9, or 10) may be linear or branched, and is preferably linear.

[0015] In addition, as the monosaccharide, glucose is preferably exemplified.

[0016] When the monosaccharide has a cyclic structure, the site of the monosaccharide to which the alkyl group having 8 to 10 carbon atoms binds (that is, the position of the OH group having a hydrogen atom substituted by the alkyl group having 8 to 10 carbon atoms) is preferably an OH group bonded to a "carbon atom on the ring bonded to the oxygen atom present on the ring".

[0017] More specifically, examples of the alkyl glucoside of the present disclosure preferably include octyl glucoside (particularly n-octyl glucoside), decyl glucoside (particularly n-decyl glucoside), and the like. Further, as the more preferable alkyl glucoside of the present disclosure, for example, the formula (A):

[0018] [Chemical formula]

[0019] (In the formula, n represents 7, 8, or 9.) The alkyl glucoside represented by is mentioned.

[0020] The alkyl glucoside of the present disclosure can be used alone or in combination of two or more. Although not particularly limited, it is particularly preferable to use a combination of octyl glucoside and decyl glucoside. When using these in combination, although not particularly limited, it is preferable to combine 0.1 to 2 parts by mass of decyl glucoside with 1 part by mass of octyl glucoside. The upper or lower limit of the said range (0.1-2 mass parts) may be 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, or 1.9 mass parts, for example. For example, the said range may be 0.2-1 mass part.

[0021] The content of the alkyl glucoside of the present disclosure in the composition of the present disclosure may be, for example, 0.01 to 5% by mass. The upper or lower limit of the range may be, for example, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, or 4.9% by mass. For example, the range may be 0.02 to 4.5% by mass.

[0022] In addition, the content of CPC in the composition of the present disclosure may be, for example, 0.005 to 0.3% by mass. The upper or lower limit of the range may be, for example, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, or 0.29% by mass. For example, the range may be 0.01 to 0.2% by mass.

[0023] Furthermore, the content mass ratio of the alkyl glucoside and CPC of the present disclosure is preferably, for example, 1 to 50 parts by mass of CPC with respect to 100 parts by mass of the alkyl glucoside of the present disclosure. The upper or lower limit of the range may be, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or 49 parts by mass. For example, the range may be 2 to 20 parts by mass.

[0024] By using the alkyl glucoside and CPC of the present disclosure in combination, an excellent bactericidal effect against Fusobacterium is achieved. Therefore, the composition containing the alkyl glucoside and CPC of the present disclosure (i.e., the composition of the present disclosure) can exhibit an excellent bactericidal effect against Fusobacterium and, as a result, an excellent plaque formation inhibitory effect. Therefore, the composition of the present disclosure can be particularly preferably used as an oral composition. Further, for example, it can be preferably used as a denture cleaning composition. Further, for example, it can also be used as a food composition. Alternatively, it can also be used as a pharmaceutical composition.

[0025] Here, the Fusobacterium is not particularly limited as long as it is a bacterium belonging to the genus Fusobacterium, which is a mediating bacterium between early adherent bacteria and late adherent bacteria in plaque formation, but Fusobacterium nucleatum is preferably exemplified.

[0026] Hereinafter, when the composition of the present disclosure is an oral composition, it will be described in more detail. The oral composition may be referred to as the oral composition of the present disclosure.

[0027] The oral composition of the present disclosure can be a solid composition or a liquid composition. The oral composition can be used, for example, as a pharmaceutical or quasi-drug. Further, the form of the oral composition of the present disclosure is not particularly limited, but can be made into forms (dosage forms) such as ointments, pastes, pastas, gels, liquids, sprays, mouthwashes, liquid dentifrices, toothpastes, and gums according to conventional methods. Among them, mouthwashes, liquid dentifrices, toothpastes, ointments, pastes, liquids, and gels are preferred.

[0028] The oral composition of the present disclosure may further contain, alone or in combination of two or more, optional components that can be formulated in an oral composition, as long as the effects are not impaired.

[0029] For example, as the surfactant, a nonionic surfactant, an anionic surfactant or an amphoteric surfactant can be blended. Specifically, for example, as the nonionic surfactant, sugar fatty acid esters such as sucrose fatty acid ester, maltose fatty acid ester, lactose fatty acid ester; fatty acid alkanolamides; sorbitan fatty acid esters; fatty acid monoglycerides; polyoxyethylene alkyl ethers with a polyoxyethylene addition coefficient of 8 to 10 and an alkyl group having 13 to 15 carbon atoms; polyoxyethylene alkyl phenyl ethers with a polyoxyethylene addition coefficient of 10 to 18 and an alkyl group having 9 carbon atoms; diethyl sebacate; polyoxyethylene hydrogenated castor oil; fatty acid polyoxyethylene sorbitan and the like can be mentioned. As the anionic surfactant, sulfate esters such as sodium lauryl sulfate, sodium polyoxyethylene lauryl ether sulfate; sulfosuccinates such as sodium lauryl sulfosuccinate, sodium polyoxyethylene lauryl ether sulfosuccinate; acyl amino acid salts such as sodium cocoyl sarcosinate, sodium lauroyl methyl alaninate; sodium cocoyl methyl taurine and the like can be mentioned. As the amphoteric ion surfactant, betaine type activators such as lauryldimethylaminoacetic acid betaine, coconut oil fatty acid amide propyldimethylaminoacetic acid betaine; imidazoline type activators such as N-cocoyl-N-carboxymethyl-N-hydroxyethyl ethylenediamine sodium; amino acid type activators such as N-lauryl diaminoethyl glycine and the like can be mentioned. These surfactants can be blended alone or in combination of two or more. The blending amount is usually 0.1 to 5% by mass based on the total amount of the composition.

[0030] In addition, as flavoring agents, for example, menthol, carboxylic acid, anethole, eugenol, methyl salicylate, limonene, ocimene, n-decyl alcohol, citronellal, α-terpineol, methyl acetate, citronellyl acetate, methyleugenol, cineole, linalool, ethyllinalool, thymol, spearmint oil, peppermint oil, lemon oil, orange oil, sage oil, rosemary oil, cypress oil, perilla oil, wintergreen oil, clove oil, eucalyptus oil, pimento oil, d-camphor, d-borneol, star anise oil, cinnamon oil, cinnamaldehyde, mint oil, vanillin and other fragrances can be used. These can be blended alone or in combination of two or more at, for example, 0.001 to 1.5% by mass based on the total amount of the composition.

[0031] In addition, as sweetening agents, for example, sodium saccharin, acesulfame potassium, stevioside, neohesperidin dihydrochalcone, perillartine, thaumatin, aspartylphenylalanyl methyl ester, p-methoxycinnamic aldehyde and the like can be used. These can be blended at, for example, 0.01 to 1% by mass based on the total amount of the composition.

[0032] Furthermore, as wetting agents, sorbitol, ethylene glycol, propylene glycol, glycerin, 1,3-butylene glycol, polypropylene glycol, xylitol, maltitol, lactitol, polyoxyethylene glycol and the like can be blended alone or in combination of two or more.

[0033] As preservatives, parabens such as methyl paraben, ethyl paraben, propyl paraben, butyl paraben, sodium benzoate, phenoxyethanol, alkyldiaminoethyl glycine hydrochloride and the like can be blended.

[0034] As colorants, legal dyes such as Blue No. 1, Yellow No. 4, Red No. 202, Green No. 3, mineral dyes such as ultramarine, fortified ultramarine, dark blue, titanium oxide and the like may be blended.

[0035] As a pH adjuster, citric acid, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, glycerophosphoric acid, acetic acid, nitric acid, or chemically possible salts thereof such as sodium hydroxide may be blended. These can be blended alone or in combination of two or more so that the pH of the composition is in the range of 4 to 8, preferably 5 to 7. The blending amount of the pH adjuster may be, for example, 0.01 to 2% by weight.

[0036] In the oral composition of the present disclosure, further, as a medicinal ingredient, for example, vitamin E such as dl-α-tocopherol acetate, tocopherol succinate, or tocopherol nicotinate, amphoteric bactericides such as dodecyldiaminoethyl glycine, nonionic bactericides such as triclosan, isopropylmethylphenol, and hinokitiol, anionic bactericides such as sodium lauroyl sarcosinate, cationic bactericides such as chlorhexidine hydrochloride and benzethonium chloride, enzymes such as dextranase, amylase, protease, mutanase, lysozyme, and lysing enzyme (lytech enzyme), alkali metal monofluorophosphates such as sodium monofluorophosphate and potassium monofluorophosphate, fluorides such as sodium fluoride and stannous fluoride, tranexamic acid and epsilon-aminocaproic acid, aluminum chlorhydroxyl allantoin, dihydrocholesterol, glycyrrhetinic acid, glycyrrhizic acid, sodium copper chlorophyllin, glycerophosphate, chlorophyll, sodium chloride, caropeptide, allantoin, carbazochrom, hinokitiol, potassium nitrate, paratinit, etc. can be blended alone or in combination of two or more.

[0037] In addition, as a base, it is also possible to add alcohols, silicon, apatite, white petrolatum, paraffin, liquid paraffin, microcrystalline wax, squalane, plastic base, etc.

[0038] In addition, the oral composition of the present disclosure can be prepared by a known method or a method that can be easily conceived from a known method. For example, it can be prepared by appropriately mixing the alkyl glucoside and CPC of the present disclosure and other components as necessary.

[0039] The subject to which the composition of the present disclosure (particularly the oral composition of the present disclosure) is applied is not particularly limited, and humans and non-human mammals are preferably mentioned. As non-human mammals, livestock and pets are preferable, and more specifically, for example, dogs, cats, mice, rats, horses, cows, sheep, monkeys, etc. can be mentioned. In addition, as described above, since the oral composition of the present disclosure contains a combination of the alkyl glucoside and CPC of the present disclosure and can efficiently sterilize Fusobacterium, which is a mediating bacterium, it can be said that it is particularly suitable for applying to the oral cavity of a subject in which plaque has not been formed or is in the process of formation (late adherent bacteria have not adhered).

[0040] In addition, the description of the oral composition of the present disclosure described above can also be directly applicable to the composition of the present disclosure that is not used as an oral composition (for example, when it is particularly preferably used for denture cleaning), as long as there is no contradiction in the technical field.

[0041] In addition, in this specification, "comprising" includes "consisting essentially of" and "consisting of" (The term "comprising" includes "consisting essentially of” and "consisting of."). In addition, the present disclosure includes all arbitrary combinations of the constituent elements described in this specification.

[0042] In addition, the various characteristics (properties, structures, functions, etc.) described for each of the above-described embodiments of the present disclosure can be combined in any way when specifying the subject matter included in the present disclosure. That is, the present disclosure includes all the subject matters composed of all possible combinations of the characteristics described in this specification.

Examples

[0043] Hereinafter, embodiments of the present disclosure will be described more specifically with examples, but the embodiments of the present disclosure are not limited to the following examples. Note that the concentration (%) indicating various compositions prepared in the following studies is w / v%, and since the solvent is water and the concentration is relatively low, it can be approximated with almost no numerical difference from mass% (w / w%).

[0044] The following three types of alkyl glucosides were used in the study. n-octyl glucoside (C8 glucoside) n-decyl glucoside (C10 glucoside) n-dodecyl glucoside (C12 glucoside)

[0045] Note that in the alkyl glucoside represented by formula (A):

[0046]

Chemical formula

[0047] Among the alkyl glucosides represented by the formula, when n = 7, it is the above-mentioned C8 glucoside, when n = 9, it is the above-mentioned C10 glucoside, and when n = 11, it is C12 glucoside.

[0048] Using the above C8 glucoside, C10 glucoside, and C12 glucoside, and CPC, according to the composition in Table 1, each component was mixed to prepare paste-like compositions A and B. Note that the numerical values of each component in Table 1 indicate mass%. The dentifrice base is a mixture obtained by adding an abrasive, a thickener, a fragrance, a sweetener, a preservative, etc. to purified water, concentrated glycerin, sorbitol solution, and calcium carbonate.

[0049]

Table 1

[0050] Weighed 1 g each of Compositions A and B in Table 1 into 50-ml tubes, added 3 ml of sterilized distilled water, and vigorously stirred with a shaker for 10 minutes to prepare test reagent solutions (Test Reagent Solutions A and B).

[0051] Also, as test bacteria, two subspecies of the following Fusobacterium were used. Bacteria 1: Fusobacterium nucleatum subsp. nucleatum ATCC23726 Bacteria 2: Fusobacterium nucleatum subsp. nucleatum ATCC25586

[0052] Inoculated each of the test bacteria into 10 ml of GAM broth medium (Nissui Pharmaceutical Co., Ltd.) and anaerobically cultured at 37°C for 2 days. The culture solution was used as the test bacterial solution.

[0053] Mixed 200 μl of the test reagent solution A or B (or 200 μl of water) with 200 μl of the test bacterial solution. 100 μl of the mixed solution was collected 30 seconds after mixing, and 900 μl of drug-inactivated PBS with soybean lecithin and Tween 80 added to final concentrations of 0.07% and 0.5% respectively in phosphate-buffered saline (PBS) was added (the mixed solution was diluted 10-fold) to inactivate the bactericidal action of the bactericide. Also, the mixed solution was serially diluted with drug-inactivated PBS, and the mixed solution was diluted 1 ~10 7 times (serial mixed solution dilutions).

[0054] 100 μl each of the prepared serial mixed solution dilutions was spread on CDC anaerobic bacteria sheep blood agar medium (Nippon Becton Dickinson Co., Ltd.) and anaerobically cultured at 37°C for 3 days, and the viable cell count was counted.

[0055] The results are shown in Fig. 1. Fig. 1 is a graph with Log (number of viable bacteria) CFU / ml on the vertical axis, and the detection limit for this value is 2. (If the value is less than 2, it indicates that sterilization has been achieved up to less than 100 CFU.) Composition A containing C12 glucoside and CPC showed no bactericidal effect against Fusobacterium, while it was found that Composition B containing C8 glucoside, C10 glucoside, and CPC showed a bactericidal effect against Fusobacterium. Note that no bactericidal effect against Fusobacterium was observed with CPC alone. Also, when using the composition obtained by removing CPC from Composition B, almost no bactericidal effect against Fusobacterium was observed.

[0056] From the above, it was found that even when C12 glucoside and CPC are used in combination, no bactericidal effect against Fusobacterium is achieved, but when C8 glucoside and / or C10 glucoside are used in combination with CPC, an especially excellent bactericidal effect against Fusobacterium is achieved.

Claims

The composition for killing Fusobacterium, comprising an alkyl glucoside having a structure in which a linear alkyl group having 8 to 10 carbon atoms is bonded to glucose and cetylpyridinium chloride. The composition for suppressing plaque formation, comprising an alkyl glucoside having a structure in which a linear alkyl group having 8 to 10 carbon atoms is bonded to glucose and cetylpyridinium chloride. The alkyl glucoside according to claim 1 or 2, wherein the alkyl glucoside is Formula (A): 【Chemical 1】 (In the formula, n represents 7, 8, or 9.) The alkyl glucoside represented by The composition according to claim 1 or 2. The composition according to any one of claims 1 to 3, containing 0.01 to 5% by mass of the alkyl glucoside. The composition according to any one of claims 1 to 4, containing 0.005 to 0.3% by mass of the cetylpyridinium chloride. Claim 6 The composition according to any one of claims 1 to 5, which is an oral composition.

Images